MX2 is an interferon-induced inhibitor of HIV-1 infection
about
Misdelivery at the Nuclear Pore Complex-Stopping a Virus Dead in Its TracksInterferon-alpha, immune activation and immune dysfunction in treated HIV infectionThe Curious Case of Type I IFN and MxA: Tipping the Immune Balance in AIDSGene expression analysis of a panel of cell lines that differentially restrict HIV-1 CA mutants infection in a cyclophilin a-dependent mannerLv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to IntegrationEvolutionary Analyses Suggest a Function of MxB Immunity Proteins Beyond Lentivirus RestrictionEvolution of Cell-Autonomous Effector Mechanisms in Macrophages versus Non-Immune CellsTracking interspecies transmission and long-term evolution of an ancient retrovirus using the genomes of modern mammalsThe KT Jeang Retrovirology prize 2015: Paul BieniaszImmune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import.Cyclophilins and nucleoporins are required for infection mediated by capsids from circulating HIV-2 primary isolates.Resistance to simian immunodeficiency virus low dose rectal challenge is associated with higher constitutive TRIM5α expression in PBMCA NMF based approach for integrating multiple data sources to predict HIV-1-human PPIs.Cyclin F/FBXO1 Interacts with HIV-1 Viral Infectivity Factor (Vif) and Restricts Progeny Virion Infectivity by Ubiquitination and Proteasomal Degradation of Vif Protein through SCFcyclin F E3 Ligase MachineryNuclear trafficking of the HIV-1 pre-integration complex depends on the ADAM10 intracellular domain.HIV-1 Tat second exon limits the extent of Tat-mediated modulation of interferon-stimulated genes in antigen presenting cells.A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infectionConformational dynamics of dynamin-like MxA revealed by single-molecule FRET.Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic ControllersInteractions between HIV-1 and the cell-autonomous innate immune system.Host and viral determinants of Mx2 antiretroviral activityTransfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factorMxB binds to the HIV-1 core and prevents the uncoating process of HIV-1Mouse knockout models for HIV-1 restriction factors.Optimizations of siRNA design for the activation of gene transcription by targeting the TATA-box motif.Innate and adaptive immune responses in male and female reproductive tracts in homeostasis and following HIV infection.Interferon-stimulated genes: a complex web of host defenses.Host and viral determinants for MxB restriction of HIV-1 infection.Structural insight into HIV-1 restriction by MxB.Compensatory substitutions in the HIV-1 capsid reduce the fitness cost associated with resistance to a capsid-targeting small-molecule inhibitor.Multifaceted activities of type I interferon are revealed by a receptor antagonist.Short communication: Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages.Contribution of MxB oligomerization to HIV-1 capsid binding and restrictionPlastic proteins and monkey blocks: how lentiviruses evolved to replicate in the presence of primate restriction factors.BCA2/Rabring7 targets HIV-1 Gag for lysosomal degradation in a tetherin-independent manner.HIV-1 Vpr induces interferon-stimulated genes in human monocyte-derived macrophages.Role of nucleotide binding and GTPase domain dimerization in dynamin-like myxovirus resistance protein A for GTPase activation and antiviral activity.The Broad-Spectrum Antiviral Protein ZAP Restricts Human RetrotranspositionA triple-arginine motif in the amino-terminal domain and oligomerization are required for HIV-1 inhibition by human MX2
P2860
Q26801484-F453AA19-9C24-4EA5-A9EC-7C005E747F8AQ26861003-1888648A-D6B5-4642-B1B2-65AFFBD66549Q26995244-11BB843A-470E-40A6-8537-DC1667062CC5Q28541423-561278D0-478D-47A2-8ADD-4DA224D7CBFCQ28546614-340710A7-0A9F-4082-91FE-1FFDB6C13D0CQ28551681-A825A41F-51AC-44E4-AFC5-8F78374B7530Q28559840-5E77D3FE-A0FD-4047-9475-CB9C2683FD83Q28602397-3B02BA61-18F6-4C4D-8807-45FF4B723526Q28606741-E7276F6D-8DC1-449A-BD84-09F93E81B03AQ30362489-F979EEA5-18A2-41E6-994E-12FE7602B840Q30385766-9CCF68AB-2396-4A08-9211-90EDDE11392FQ30400372-FE910CAC-42B1-48E8-9293-0F0713FA74FDQ30579576-2DBFCC1B-CF22-47CB-A184-CB05D84A6094Q31054893-876F532D-4863-44D9-A9A4-A95894E4AB3AQ33567848-B245F295-17F1-43D1-B103-C02A2F78D72AQ33601292-20AD6AE6-C299-489C-874F-1ACBD84964D3Q33678960-CEDF114D-6648-49AA-B110-A3C969EA22B5Q33683355-7B0182BC-2F59-4C02-8F7C-BBE9E2ABE06BQ33762981-53480432-ECDE-430A-B1E8-E9D9EE0EDA47Q33828507-E60C8EEA-4A87-438B-91BF-7704C8F0539EQ33895123-30322A5B-4C70-4F79-89F6-7A09F19B4573Q33900299-F916705E-210D-471A-AE87-A49B61039490Q34059183-4BAAE1EC-D8B9-47F1-9A3D-6A9E2B75AEA5Q34091405-D0B78290-EAEB-42DB-AE36-8E78DEC71E11Q34161853-F4A5EF02-633E-4F7E-BDF1-95FED8D27CABQ34252830-B7ED2CA9-4041-4035-AE47-4FEC1D55E8D7Q34339797-53784564-335C-43E0-A910-113CEF2CD689Q34405609-8DFF90ED-F390-4DCC-9339-4E31F37A0B86Q34422979-FB2422DC-AAB4-4054-97A1-979617CD8866Q34615762-DEE4D99C-7D82-4881-AD37-3B8F501D3465Q34992565-883365A8-5280-4FE9-8825-4D87308C046FQ35031568-5C20E6D1-CDE8-4942-A9D0-A74AE23E7FB1Q35036587-C948C1C6-1C49-45E8-81F2-DCB684E7F9A9Q35111033-834CABDE-6498-410C-B540-2DC1E84C71DCQ35151869-22A2AC2D-41D6-41EB-BC00-FBF4E12E3440Q35172448-4E4ECDA2-F8A1-4090-ADD5-A26887E541B4Q35234824-FB221E46-CE61-49A1-AE8C-B54E02DBFF19Q35608130-0AADAC0B-7091-4009-8E6B-00AAB6DDCFEBQ35639494-B104DA53-006C-4055-8CC1-B52E5CDD390FQ35641044-EF0EA207-BB4B-445F-888D-028C95DA5E54
P2860
MX2 is an interferon-induced inhibitor of HIV-1 infection
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
MX2 is an interferon-induced inhibitor of HIV-1 infection
@ast
MX2 is an interferon-induced inhibitor of HIV-1 infection
@en
MX2 is an interferon-induced inhibitor of HIV-1 infection
@en-gb
MX2 is an interferon-induced inhibitor of HIV-1 infection
@nl
type
label
MX2 is an interferon-induced inhibitor of HIV-1 infection
@ast
MX2 is an interferon-induced inhibitor of HIV-1 infection
@en
MX2 is an interferon-induced inhibitor of HIV-1 infection
@en-gb
MX2 is an interferon-induced inhibitor of HIV-1 infection
@nl
prefLabel
MX2 is an interferon-induced inhibitor of HIV-1 infection
@ast
MX2 is an interferon-induced inhibitor of HIV-1 infection
@en
MX2 is an interferon-induced inhibitor of HIV-1 infection
@en-gb
MX2 is an interferon-induced inhibitor of HIV-1 infection
@nl
P2093
P2860
P3181
P356
P1433
P1476
MX2 is an interferon-induced inhibitor of HIV-1 infection
@en
P2093
Charles M Rice
John W Schoggins
Julia Bitzegeio
Masahiro Yamashita
Melissa Kane
Paul D Bieniasz
Sebla B Kutluay
Shalini S Yadav
Theodora Hatziioannou
Trinity Zang
P2860
P2888
P304
P3181
P356
10.1038/NATURE12653
P407
P50
P577
2013-10-13T00:00:00Z
P6179
1017549973